FRANKLIN LAKES, N.J. (October 3, 2024) – BD (Becton, Dickinson and Company), a global leader in medical technology, will highlight its newest innovations in drug delivery systems at CPhI Milan 2024 on October 8th and 9th in Milan, Italy. The event is a premier global platform for pharmaceutical professionals, focusing on innovations in drug delivery and packaging systems. This year's showcase at booth #20A65 will emphasize BD’s continued commitment to advancing healthcare through cutting-edge drug delivery solutions and feature an array of innovative products designed to meet the growing demands of pharmaceutical and biotech industries across a range of therapeutic areas.
Featured products include:
- BD iDFill™ Individual Prefillable Syringe Identification°: A Radio Frequency Identification (RFID) based solution for prefillable syringes (PFS) which aims to enhance efficiency and improve traceability during fill-and-finish operations. BD iDFill™ is also a finalist for the 2024 CPhI Manufacturing Excellence Award.
- BD Neopak™ XtraFlow™ Glass Prefillable Syringe: Designed for subcutaneous delivery of high-viscosity biologics with a shorter 8mm needle length and thinner wall technology. BD’s product demonstration booth will offer attendees an interactive experience, showcasing how BD Neopak™ XtraFlow™ Glass Prefillable Syringe is allowing drug developers to Flow Beyond Limits.
- BD SCF™ PremiumCoat® 1-3mL Plunger Stopper: Engineered to support the subcutaneous injection of complex biologics and viscous solutions through reduced* glide force and glide force variability1, and guarantee of no ribs not touching to support container closure integrity2.
"At BD, our mission is to support the global health community with drug delivery solutions that are as innovative as they are reliable," said Fernand Goldblat, VP/GM BD Medical-Pharmaceutical Systems, PFS platform. "Our presence at CPhI Milan reaffirms our commitment to collaboration and partnership with biopharmaceutical companies to bring next-generation solutions to market."
BD will have other products on display, including BD Effivax™ Glass Prefillable Syringe for vaccines, BD Libertas™ Wearable Injector** and BD Evolve™ On-body Injector*** wearable solutions, as well as BD Physioject™ Disposable Autoinjector and BD Vystra™ Disposable Pen for biologics. These products and innovative solutions exemplify BD's leadership in offering a broad range of injection solutions to enable delivery of vaccines, treatments such as GLP-1s and other next generation treatments for chronic disease.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts:
Media: Investors:
Troy Kirkpatrick Adam Reiffe
VP, Public Relations Sr. Director, Investor Relations
858.617.2361 201.847.6927
troy.kirkpatrick@bd.com
° BD iDFill™ is in development, and accordingly some statements are forward-looking and subject to various risks and uncertainties. Any actual solution placed on the market may differ.
* When compared to the BD SCF™ FluroTec® Plunger Stopper. Results are based on a sample of 100 pieces of BD Flurotec® and BD SCF™ PremiumCoat®. Variables compared were Mean (glide force reduction) and standard deviation (glide force variability).
1TR20234488 Le Pont-de-Claix, France; Becton, Dickinson and Company; 2024.
2BD SCF™ PremiumCoat® Plunger Stopper 1-3mL Customer quality specifications. Le Pont-de-Claix, France; Becton, Dickinson and Company; 2023.
**BD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification. BD Libertas™ Wearable Injector.
***BD Evolve™ On-body Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Evolve™ On-body Injector is a device component intended for drug-device combination products and subject to EU CE mark certification but not FDA 510(k) clearance.
PremiumCoat is a registered trademark of AptarGroup, Inc.
FluroTec is a registered trademark of West Pharmaceutical Services, Inc.